Bright Biologics

At Bright Biologics, we are using VHH antibodies as building blocks to develop novel, next-generation bispecific and multispecific antibody drugs to improve clinical outcomes for cancer patients with resistance and/or unmet medical needs. We focus on developing novel Bispecific Antibody-Drug Conjugates (BsADCs) and T-Cell Engagers (TCEs) to address the heterogeneity of solid tumors, the leading cause of tumor relapse when treated with monospecific TAA-targeting therapies that only kill one subpopulation of cancer cells. We leverage cutting-edge technology and a state-of-the-art screening platform for VHH antibody discovery, employing MOA mimicry in vitro and ex vivo assays to evaluate and select functional antibodies. Several first-in-class BsADCs have been developed and have completed proof of concept (POC) studies both in vitro and in vivo. We are seeking potential partners to co-develop our lead BsADC molecules as they progress toward clinical trials. We welcome all forms of collaboration and invite you to contact us to initiate a discussion if you are interested.